Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02998151 · ClinicalTrials.gov registry record · Early Phase 1
Neurophysiological and Acute Pharmacological Studies in FXS Patients
A Early Phase 1 study of Fragile X Syndrome, sponsored by Children's Hospital Medical Center, Cincinnati.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 29
- Enrollment target
- 1
- Study location
NCT02998151: Completed Early Phase 1 study of Fragile X Syndrome, sponsored by Children's Hospital Medical Center, Cincinnati.
NCT02998151 is a Early Phase 1 study of Fragile X Syndrome that has completed, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 29 participants, below the 100-participant average among 16 other Fragile X Syndrome trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02998151, a Early Phase 1 study of Fragile X Syndrome, has completed, sponsored by Children's Hospital Medical Center, Cincinnati.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 29 participants
- Enrollment target
- 1
- Study location
Study Summary
The aim of this study is to utilize neurophysiologic assessments, behavioral measures and clinical measures to assess how much deficits associated with Fragile X Syndrome from pre-dose to post-dose using pharmacology.
Primary Outcome
EEG relative gamma power at rest was calculated as the percent of power in the gamma frequencies relative to the sum of power in all frequency bands, averaged across electrodes, and calculated separately at pre-dose and post-dose timepoints. To assess the impact of drug, the pre-dose relative gamma power was subtracted from post-dose relative gamma power. Higher numbers indicate more relative gamma power post-dose; lower numbers indicate more relative gamma power pre-dose.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Acamprosate
- DRUG Minocycline
- DRUG Lovastatin
- DRUG Baclofen
Study Locations (1)
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2016-01 |
| Est. Completion | 2020-11 |
| Phase | Early Phase 1 |
What the finished NCT02998151 record still lists
NCT02998151 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 100-participant average among 16 other Fragile X Syndrome trials with a reported enrollment target (71% lower).
The record links to 1 condition, with Fragile X Syndrome appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.
NCT02998151 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT02998151 about?
NCT02998151 is a clinical study titled "Neurophysiological and Acute Pharmacological Studies in FXS Patients". The aim of this study is to utilize neurophysiologic assessments, behavioral measures and clinical measures to assess how much deficits associated with Fragile X Syndrome from pre-dose to post-dose using pharmacology.
What is the current status of trial NCT02998151?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 29 participants. The study started on 2016-01. Estimated completion is 2020-11.
What conditions does trial NCT02998151 study?
This clinical trial studies the following conditions: Fragile X Syndrome.
What interventions are being tested in trial NCT02998151?
The interventions under investigation include: Placebo (DRUG), Acamprosate (DRUG), Minocycline (DRUG), Lovastatin (DRUG), Baclofen (DRUG).
Who is sponsoring clinical trial NCT02998151?
This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02998151 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fragile X Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02998151's enrollment target sits among peer trials
29 13th of 16 higher than 4 of 16 other Fragile X Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Fragile X Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Physical Activity and Community EmPOWERment Project
RECRUITING · NA
-
Tracking Early Emergence of Sound Perception Impairments in FXS With Multimodal fNIRS/EEG- Infant
RECRUITING · NA
-
Web Intervention for Parents of Youth With Genetic Syndromes (WINGS)
RECRUITING · NA
-
Tracking Early Emergence of Sound Perception Impairments in FXS With Multimodal fNIRS/EEG-Preschool Age
RECRUITING · NA
-
Speech-in-noise Perception in Autism and Fragile X
RECRUITING · NA
-
Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02429557 · 29 participants · Phase 1
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
- NCT02568878 · 29 participants · Phase 3
Creatine for Depressed Male and Female Methamphetamine Users
- NCT03014401 · 29 participants · NA
The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis
- NCT03128996 · 29 participants · Phase 1
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia